Genprex files 1:22 reverse stock split to address Nasdaq bid price deficiency; faces delisting risk

Genprex, Inc.

Reverse stock split at 1:22 ratio effective July 16, 2026; shares outstanding to reduce from ~11.1M to ~505K.
Received Nasdaq delisting notice on June 10, 2026 for failing to maintain $1.00 bid price; requested hearing.
Acclaim-1 Phase 2a enrolling; Acclaim-3 Phase 2 expansion enrolling, interim analysis expected H1 2027.
Identified TROP-2 and PTEN as predictive biomarkers for REQORSA; plan to evaluate high TROP-2 expression.
No guarantee reverse split will regain compliance; risk of delisting and adverse impact on stock price and capital access.

item 3.03 item 5.03 item 7.01 item 8.01 item 9.01

Featured in Daily 8-K Digest

Selected #10 for 2026-07-14. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.